title: p53 is not mutated in hepatocellular carcinomas from Alaska Natives.
abstract: Hepatocellular carcinoma is common among Alaska Natives. The known risk factor in this population is hepatitis B viral infection; fungal toxins, including aflatoxin B1, have not been detected in foodstuffs. In this series of 14 patients (including 4 siblings and 2 second cousins), 3 patients were less than 12 years old at diagnosis of hepatocellular carcinoma, 8 patients were 13-24 years old, and 3 patients were more than 60 years old. Since p53 mutations occur in 29% of hepatocellular carcinomas worldwide, we tested the tumors for p53 mutations and serum samples for anti-p53 antibodies. Serum samples from these 14 patients did not contain detectable levels of anti-p53 antibodies. Loss of heterozygosity within the p53 locus was not detected in any of 9 informative cases. Immunohistochemical analysis for p53 protein accumulation was negative in all of 11 tumors. DNA sequence analysis of 12 tumor samples showed no evidence of p53 mutation in the highly conserved regions included in exons 5-8. These data, combined with one case from a previous report, indicate a mutation frequency of 0 of 13, which differs significantly from the worldwide frequency of 29% (chi 2 3.9; P = 0.048). These results indicate that liver carcinogenesis among Alaska Natives occurs independently of a traditional p53 pathway. The familial clustering and early onset in this population strongly suggest an inherited genetic predisposition to develop liver cancer. Germline mutations in a tumor suppressor or a cancer susceptibility gene are likely. Future studies of these samples should include investigations of candidate suppressor or susceptibility genes which map to chromosomal regions commonly deleted in liver cancers.
authors.affiliation: Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892.
authors.forename: V M
authors.initials: VM
authors.lastname: De Benedetti
authors.forename: J A
authors.initials: JA
authors.lastname: Welsh
authors.forename: G E
authors.initials: GE
authors.lastname: Trivers
authors.forename: A
authors.initials: A
authors.lastname: Harpster
authors.forename: A J
authors.initials: AJ
authors.lastname: Parkinson
authors.forename: A P
authors.initials: AP
authors.lastname: Lanier
authors.forename: B J
authors.initials: BJ
authors.lastname: McMahon
authors.forename: W P
authors.initials: WP
authors.lastname: Bennett
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000413:Alaska; D000906:Antibodies / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000208:ethnology / Q000235:genetics / Q000378:metabolism*; D002648:Child; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D005091:Exons / Q000235:genetics; D005260:Female; D016147:Genes, Tumor Suppressor / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D007198:Indians, North American / Q000235:genetics*; D004930:Inuit / Q000235:genetics*; D008113:Liver Neoplasms / Q000208:ethnology / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics; D017422:Sequence Analysis, DNA; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000276:immunology
chemical_list: D000906:Antibodies; D016159:Tumor Suppressor Protein p53